Address correspondence to Remon Abu-Elyazeed, GlaxoSmithKline Biologicals, 150 Beach Road, #22-00 Gateway West, Singapore 189720. E-mail:
Authors’ addresses: Robert G. Sacy, St. Georges Hospital, Achrafieh, Lebanon, Telephone: + 961 1 585700, Fax: + 961 1 582560, E-mail:
Acknowledgments: The study was supported by GlaxoSmithKline Biologicals. The authors thank Dr. Hussein Makki and Drs. Carlo Akatcherian and Raymond Michael for their significant contributions in recruiting subjects at Hammoud Hospital, Saida, and Hotel Dieu de France Hospital, Beirut, respectively; and Mr. Vincent Mazraanin for his assistance in conducting all the necessary laboratory procedures at Nini Hospital, Tripoli, North Lebanon.
Battegay M, Gust ID, Feinstone SM, 1995. Hepatitis A virus. Mandell JL, Benett JE, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingstone 1636–1656.
Hadler SC, 1991. Global impact of hepatitis A virus infection changing patterns. Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 14–20
Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E, 1994. Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol Infect 113 :113–120.
Werzbeger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, 1992. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 :453–457.
Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB, Boslego JW, 1994. Protection against hepatitis A by an inactivated vaccine. JAMA 271 :1328–1334.
Andre FE, D’Hondt E, Delem A, Safary A, 1992. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 10 (Suppl 1):S160–S168.
Andre F, Van Damme P, Safary A, Banatvala J, 2000. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 1 :9–23.
Lebanese decree no 8733. Fixing the minimum wages of the employees and workers as well as the increase of the cost of living. Lebanese Official Gazette (in Arabic: Jaride Al Rasmiye) Lebanon, Published on 8 July 1996.
Shammaa MH, Abu-Samra S, Salameh V, Nassar NT, 1982. The significance of anti-HAV in different population sectors in Lebanon: a comparative seroepidemiologic study. Int J Epidemiol 11 :406–409.
Kalaajieh W, Rima A, Dennaoui M, Al Khodayry R, 2000. Seroprevalence of hepatitis A antibodies in Lebanese children. Med Mal Infect 30 :757–761.
Poovorawan Y, Theamboonlers A, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, Khwanjaipanich S, Owatanapanich S, Hirsch P, 2000. Increasing susceptibility to HAV among members of the young generation in Thailand. Asian Pac J Allergy Immunol 18 :249–253.
Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE, 2001. The changing epidemiology of viral hepatitis A in Israel. Isr Med Assoc J 3 :347–351.
Halliday ML, Kang LY, Zhou TK, Hu MD, Pan QC, Fu TY, Huang YS, Hu SL, 1991. An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis 164 :852–859.
McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L, 1996. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 150 :733–739.
Salleras L, Bruguera M, Buti M, Domingez A, 2000. Prospects for vaccination against hepatitis A and B in Catalonia (Spain). Vaccine 18 (Suppl 1):S80–S82.
Germinario C, Lopalco PL, Chicanna M, Da Villa G, 2000. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 18 (Suppl 1):S83–S85.
Dominguez A, Salleras L, Carmona G, Batalla J, 2003. Effectiveness of a mass hepatitis A vaccination program in pre-adolescents. Vaccine 21 :698–701.
Demicheli V, Carniglia E, Fucci S, 2003. The use of hepatitis a vaccination in Italy: an economic evaluation. Vaccine 21 :2250–2257.
Ginsber GM, Slater PE, Shouval D, 2001. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 34 :92–99.